Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease

European Journal of Neuroscience

Volumn 13, Issue 6, 2001, Pages 1085-1092

  Costantini, Lauren C ^a,b   Cole, Douglas ^c   Chaturvedi, Pravin ^c   Isacson, Ole ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

Animal models; FK binding proteins; Mouse; Neuroprotection; Neurotrophic factors; Rat; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; IMMUNOPHILIN; LIGAND; OXIDOPAMINE; UNCLASSIFIED DRUG; V 13661;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DENERVATION; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE PROGRESSION; DOPAMINE; DOPAMINE AGENTS; ENDOTHELIAL GROWTH FACTORS; IMMUNOPHILINS; LIGANDS; LYMPHOKINES; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035062462     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816X.2001.01473.x     Document Type: Article

References (59)

1. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons
2. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions
3. Systemic administration of nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy
4. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases
5. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders
6. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease
7. Glial cell line derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons
8. Parkinson's disease, motoneuron disease and Alzheimer's disease: Origins and interrelationship
9. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine
10. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease
11. Immuophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons
12. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging
13. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate toxicity
14. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease
15. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
16. Intracerebral grafting of neuronal cell suspensions. IV. Behavioral recovery in rats with unilateral 6-OHDA lesions in different brain sites
17. Dopamine-rich grafts ameliorate whole body motor assymmetry and sensory neglect but not independent limb use in rats with 6-OHDA lesions
18. Oxidative stress and antioxidant therapy in Parkinson's disease
19. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in rat
20. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration
21. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
22. A non-immunosuppressive FKBP-12 ligand increases nerve regeneration
23. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo
24. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo
25. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons
26. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
27. Neuroprotection for Parkinson's disease
28. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease
29. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
30. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons
31. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat
32. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: A detailed account of methodology and a 6-month follow-up
33. Inhibition of T cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity
34. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients
35. Pallidotomy for Parkinson's disease
36. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats
37. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia
38. Parkinsons disease: Drug therapy
39. Dopamine agonists and neuroprotection in Parkinson's disease
40. Etiology and pathogenesis of Parkinson's disease
41. Clinical and pathological evaluation of patient with Parkinson's disease (PD) following intracerebroventricular (icv) GDNF
42. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
43. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
44. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or lateral ventricle
45. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease
46. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in rat
47. Glial cell-line derived neurotrophic factor but not transforming growth factor B3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion
48. Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients
49. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia
50. Mortality in DATATOP: A multicenter trial in early Parkinson's disease
51. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine
52. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporin A
53. High brain densities of the immunophilin FKBP colocalized with calcineurin
54. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
55. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy
56. Growth factor function in the development and maintenance of midbrain dopaminergic neurons: Concepts, facts and prospects for TGF-β
57. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease
58. Short-term GDNF treatment provides long-term rescue of lesioned nigral DA neurons in a rat model of Parkinson's disease